Myasthenia gravis (MG), the most common of autoimmune myasthenic syndromes, is characterized by antibodies directed against the skeletal muscle acetylcholine receptors (AChRs). Endplate Na + channels ensure the efficiency of neuromuscular transmission by reducing the threshold depolarization needed to trigger an action potential. Postsynaptic AChRs and voltage-gated Na + channels are both lost from the neuromuscular junction in MG. This study examined the impact of postsynaptic voltage-gated Na + channel loss on the safety factor for neuromuscular transmission. In intercostal nerve-muscle preparations from MG patients, we found that endplate AChR loss decreases the size of the endplate potential, and endplate Na + channel loss increases the threshold depolarization needed to produce a muscle action potential. To evaluate whether AChR-specific antibody impairs the function of Na + channels, we tested omohyoid nerve-muscle preparations from rats injected with monoclonal myasthenogenic IgG (passive transfer model of MG [PTMG]). The AChR antibody that produces PTMG did not alter the function of Na + channels. We conclude that loss of endplate Na + channels in MG is due to complement-mediated loss of endplate membrane rather than a direct effect of myasthenogenic antibodies on endplate Na + channels. Published by Elsevier B.V.
Introduction
Weakness in the autoimmune disease, myasthenia gravis (MG) is caused by antibodies directed against skeletal muscle acetylcholine receptors (AChR) on the muscle membrane portion of the endplate (Drachman, 1994; Vincent et al., 2003) . These antibodies reduce the number of AChRs at the endplate (Drachman, 1994; Engel and Fumagalli, 1982; Engel et al., 1977; Fambrough et al., 1973; Kaminski and Ruff, 1999; Kao and Drachman, 1977) by a combination of complementmediated membrane lysis (Engel and Fumagalli, 1982) and acceleration of AChR catabolism by receptor cross-linking (Drachman, 1994; Engel, 1994; Kao and Drachman, 1977; Vincent et al., 2003) . The secondary synaptic folds are simplified due to loss of endplate membrane (Engel, 1994; Engel et al., 1977; Engel and Santa, 1971; Maselli et al., 1991; Santa et al., 1972) . The serum level of AChR binding antibodies does not predict the severity of weakness (Drachman, 1994; Engel, 1994; Kaminski and Ruff, 1996) , but the postsynaptic membrane area correlates with the size of the endplate potentials (EPP) miniature endplate potentials (MEPP) and with the patient's clinical signs of weakness (Engel et al., 1977) .
MG is inducible in rats by immunization with foreign or self AChR (EAMG) or by passive transfer of myasthenogenic AChR binding IgG (PTMG) (Drachman, 1994; Engel, 1994; Kaminski and Ruff, 1996; Lennon and Lambert, 1980; Lindstrom et al., 1976a,b) . Weakness in PTMG begins about
